Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Fesco launches new regular container train from Moscow to Omsk

10/4/23 FESH

Shareholders of Donskoy Factory of Radiocomponents approved dividends for 6 months 2023

10/4/23 DZRD

MD Medical will obtain a primary listing on the Moscow Exchange

10/4/23 MDMG

SPB Exchange summarized the results of trading in September

10/4/23 SPBE

Moscow Exchange warned HeadHunter of non-compliance with listing requirements

10/4/23 HEAD

PhosAgro shareholders decided not to pay dividends for 6 months of 2023

10/3/23 PHOR

Abrau-Durso started producing vodka

10/3/23 ABRD

Trading volume on Moscow Exchange in September increased by 67% year-on-year

10/3/23 MOEX

Cian will obtain a primary listing on the Moscow Exchange

10/3/23 CIAN

VK is getting more and more Yandex

10/3/23 VKCO